Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | VNN1 | O95497 | 2/20 | 0.31 |
| ▸ | SSTR4 | P31391 | 2/20 | 0.31 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.31 |
| ▸ | F2R | P25116 | 1/20 | 0.31 |
| ▸ | JAK3 | P52333 | 2/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23086759 | 1.00 | LMNA (0.38) | LMNAUSP30SMN1; SMN2VNN1SSTR4 | |
| SCHEMBL16470712 | 1.00 | LMNA (0.38) | LMNAUSP30SMN1; SMN2VNN1SSTR4 | |
| SCHEMBL17747852 | 1.00 | LMNA (0.38) | LMNAUSP30SMN1; SMN2VNN1SSTR4 | |
| SCHEMBL22441066 | 0.87 | LMNA (0.38) | LMNAUSP30SMN1; SMN2JAK3ALDH1A1 | |
| SCHEMBL22441070 | 0.87 | LMNA (0.38) | LMNAUSP30SMN1; SMN2JAK3ALDH1A1 | |
| SCHEMBL23130508 | 0.87 | LMNA (0.38) | LMNAUSP30SMN1; SMN2JAK3ALDH1A1 | |
| SCHEMBL1437707 | 0.82 | LMNA (0.39) | LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL26963364 | 0.81 | GSK3B (0.38) | LMNAUSP30SMN1; SMN2F2RJAK3 | |
| SCHEMBL25339588 | 0.81 | GSK3B (0.38) | LMNAUSP30SMN1; SMN2F2RJAK3 | |
| SCHEMBL26963314 | 0.81 | GSK3B (0.38) | LMNAUSP30SMN1; SMN2F2RJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2367800-B9 | SUBSTITUTED PYRIMIDINES FOR THE TREATMENT OF DISEASES SUCH AS CANCER | IPHARMA H K LTD (HK) | 2021-10-20 | — | — | EP | disclosed |
| EP-2367800-B1 | SUBSTITUTED PYRIMIDINES FOR THE TREATMENT OF DISEASES SUCH AS CANCER | BOEHRINGER INGELHEIM INT (DE) | 2018-02-28 | — | — | EP | disclosed |
| US-20150376141-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INT (DE) | 2015-12-31 | — | — | US | disclosed |
| US-20110288071-A1 | SUBSTITUTED PYRIMIDINES FOR THE TREATMENT OF DISEASES SUCH AS CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-24 | — | — | US | disclosed |
| EP-2367800-A2 | NEW COMPOUNDS | Boehringer Ingelheim International GmbH (DE) | 2011-09-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376141-A1 | NEW COMPOUNDS | CCNA1, MKI67, CCNT1 | LMNA 209/4885USP30 4572/4885SMN1; SMN2 381/4885 |
| US-20110288071-A1 | SUBSTITUTED PYRIMIDINES FOR THE TREATMENT OF DISEASES SUCH AS CANCER | TYMP, HPRT1, TYMS | LMNA 1415/4885USP30 4300/4885SMN1; SMN2 504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.